Compare ResMed Inc. (RMD) vs Shopify Inc. (SHOP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Shopify Inc. — how do they compare? ResMed Inc. trades at $228.81 (market cap $31.89B), while Shopify Inc. trades at $169.02 (market cap $211.73B). The key difference: Shopify Inc. is far larger — about 6.6× ResMed Inc.'s market cap, and ResMed Inc. pays a 1.16% dividend while Shopify Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold ResMed Inc. for 51 Days and Shopify Inc. for 78 Days on average.
| RMD | SHOP | |
|---|---|---|
Market Cap | $31.89B | $211.73B |
Volume | 618,314 | 7,146,651 |
Sector | Health | Technology |
52-Week High | $277.88 | $179.01 |
52-Week Low | $182.82 | $95.40 |
Typical Hold Time | 51 Days | 78 Days |
Enterprise Value | $31.24B | $206.96B |
Dividend Yield | 1.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $228.37, up 1.06% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15B in 2025, with a robust net income margin of 26.94%. Recent news highlights management's presentation at the Morgan Stanley Healthcare Conference and an upcoming Q1 2027 earnings report.
The outlook is positive, supported by earnings growth targets of 12-14% and a consensus price target of $242.70. Key risks include competitive pressures and ongoing legal investigations. Institutional buying activity and analyst upgrades reflect confidence, but investors should monitor execution against growth targets and any developments from the legal probe.
SHOP trades at $168.69, up 1.66% today, with strong technical momentum as moving averages signal bullish sentiment. The company shows robust revenue growth from $5.6B in 2022 to $11.56B in 2025, though recent Q4 2025 EPS missed expectations. Analyst consensus remains bullish with 67% buy ratings and a $168.63 price target, while Shopify's AI innovations like Canvas and open AI agent access position it competitively against Amazon.
Outlook: Shopify's expanding merchant solutions and AI-driven commerce tools support growth, but high valuation multiples (P/E 111.19) and overbought RSI levels pose near-term risks. Investors should weigh strong fundamentals against premium pricing and competitive pressures in the e-commerce sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Shopify Inc.
Shopify Inc. provides a cloud-based commerce platform. The Company offers a platform for merchants to create an omni-channel experience that helps showcase the merchant's brand.
Read more on SHOP →
